Related Experiment Video
Updated: Jun 23, 2026
06:18
Chimeric Antigen Receptor T Cell Manufacturing on an Automated Cell Processor
Published on: August 18, 2023
Combination products regulation at the FDA
1Office of Combination Products, US Food and Drug Administration, Rockville, Maryland, USA. kristina.lauritsen@fda.hhs.gov
Clinical Pharmacology and Therapeutics
|April 22, 2009
Summary
The US Food and Drug Administration (FDA) oversees drug, biologic, and device safety. Technological advancements are blurring the lines between regulatory centers like CDER, CDRH, and CBER.
Area of Science:
- Regulatory Science
- Public Health Policy
- Medical Product Oversight
Background:
- The US Food and Drug Administration (FDA) ensures public health by regulating medical products.
- Different centers historically managed drugs (CDER), devices (CDRH), and biologics (CBER).
Purpose of the Study:
- To examine the evolving regulatory landscape at the FDA.
- To understand the impact of technological advancements on center distinctions.
Main Methods:
- Analysis of FDA organizational structure and regulatory mandates.
- Review of recent technological trends impacting medical products.
Main Results:
- Technological progress is increasingly merging product categories.
- Traditional distinctions between CDER, CDRH, and CBER are becoming less defined.
Conclusions:
- The FDA faces challenges in adapting its center structure to new technologies.
- Regulatory harmonization across centers may be necessary for future efficiency.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...